<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060437</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000301951</org_study_id>
    <secondary_id>NCI-03-C-0157</secondary_id>
    <secondary_id>NCI-5970</secondary_id>
    <nct_id>NCT00060437</nct_id>
    <nct_alias>NCT00058708</nct_alias>
  </id_info>
  <brief_title>Perifosine in Treating Patients With Metastatic, Androgen-Independent Prostate Cancer</brief_title>
  <official_title>A Phase II Trial Of Oral Perifosine In Patients With Metastatic Androgen Independent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as perifosine use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who&#xD;
      have prostate cancer that no longer responds to androgen ablation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the 4-month progression-free survival rate, as measured by prostate-specific&#xD;
           antigen and clinical criteria, in patients with metastatic androgen-independent prostate&#xD;
           cancer treated with perifosine.&#xD;
&#xD;
        -  Determine the side-effect profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Course 1: Patients receive oral perifosine twice on day 1 and once daily on days 2-21.&#xD;
&#xD;
        -  All subsequent courses: Patients receive oral perifosine once daily on days 1-21.&#xD;
&#xD;
      In all courses, treatment repeats every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 22-46 patients will be accrued for this study within&#xD;
      approximately 1.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perifosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate, meeting all of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Metastatic&#xD;
&#xD;
               -  Androgen-independent&#xD;
&#xD;
               -  Progressive disease while continuing to receive hormonal ablation (e.g.,&#xD;
                  luteinizing hormone-releasing hormone [LHRH] agonist)&#xD;
&#xD;
          -  Progression documented by at least 1 of the following parameters:&#xD;
&#xD;
               -  Two consecutively rising prostate-specific antigen levels, at least 1 week apart,&#xD;
                  with at least 1 measurement that is 50% above the nadir reached after the last&#xD;
                  treatment regimen (as long as the last measurement is at least 5 ng/mL)&#xD;
&#xD;
               -  At least 1 new metastatic lesion on technetium Tc 99m bone scintigraphy&#xD;
&#xD;
               -  Progression of soft-tissue metastases as measured by appropriate modalities&#xD;
                  (i.e., imaging or palpation) and demonstrated by at least 1 of the following:&#xD;
&#xD;
                    -  Development of new area of malignant disease (measurable or nonmeasurable)&#xD;
&#xD;
                    -  At least a 20% increase in the sum of the longest diameters (LD) of target&#xD;
                       lesions from the smallest sum of LD recorded since the treatment started or&#xD;
                       the appearance of 1 or more new lesions&#xD;
&#xD;
          -  Patients who have not undergone surgical castration must have a testosterone level&#xD;
             less than 50 ng/mL and continue on their LHRH agonist during study treatment&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.0 mg/dL or upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No unstable or newly diagnosed angina pectoris&#xD;
&#xD;
          -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
        Ophthalmic&#xD;
&#xD;
          -  No pre-existing retinal disease&#xD;
&#xD;
          -  No pathologic baseline electrooculogram&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception&#xD;
&#xD;
          -  Able to ingest oral medication&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biological&#xD;
             composition to perifosine (e.g., miltefosine or edelfosine)&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other active malignancies within the past 2 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the bladder&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (at least 6 weeks for nitrosoureas or&#xD;
             mitomycin)&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior flutamide&#xD;
&#xD;
          -  More than 6 weeks since prior bicalutamide or nilutamide&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior bone-seeking radioisotopes&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from any acute toxicity related to prior therapy&#xD;
&#xD;
          -  More than 3 months since prior UCN-01&#xD;
&#xD;
          -  More than 3 months since prior suramin&#xD;
&#xD;
          -  No concurrent commercial or other investigational agents or therapies intended to&#xD;
             treat the malignancy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin M. Posadas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C, Jones E, Steinberg SM, Daniels A, Figg WD, Dahut WL. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther. 2005 Oct;4(10):1133-7. Epub 2005 Oct 1.</citation>
    <PMID>16138006</PMID>
  </results_reference>
  <results_reference>
    <citation>Posadas EM, Trout A, Senderowicz AM, et al.: A phase II trial of oral perifosine in patients with metastatic androgen-independent prostate cancer (AIPC). [Abstract] SUO/NCI Urologic Oncology Meeting, December 5-6, 2003, Bethesda, MD. A-54, 38, 2003.</citation>
  </results_reference>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

